GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On November13, 2017, Galectin TherapeuticsInc. (the “Company) issued the press release attached hereto as Exhibit 99.1.

The information in this report is being furnished to this Item 7.01 and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this report.

SECTION9 – FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

GALECTIN THERAPEUTICS INC Exhibit
EX-99.1 2 d475110dex991.htm EX-99.1 EX-99.1 Exhibit 99.1     Combination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical Trial The objective response rate in advanced melanoma was 62.5% (five of eight subjects) NORCROSS,…
To view the full exhibit click here

About GALECTIN THERAPEUTICS INC. (NASDAQ:GALT)

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.